Vinva Investment Management Ltd Makes New Investment in Insulet Corporation $PODD

Key Points

• Vinva Investment Management acquired a new stake in Insulet, buying 5,942 shares (≈$1.846 million) in the third quarter.
• Insulet recently beat estimates with $1.55 EPS vs. $1.48 consensus and reported revenue of $783.8 million, up 31.2% year‑over‑year.
• Director Michael R. Minogue purchased 2,030 shares at $246.23 (≈$499,847), increasing his position by 13.14%; corporate insiders now own about 0.39% of the stock.

Vinva Investment Management Ltd acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,942 shares of the medical instruments supplier's stock, valued at approximately $1,846,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. True Wealth Design LLC raised its position in Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 72 shares during the period. Golden State Wealth Management LLC boosted its position in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 69 shares during the period. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 43 shares during the last quarter. Quent Capital LLC bought a new position in shares of Insulet during the third quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Insulet in the second quarter worth about $51,000.

Insulet Stock Up 1.4%

Shares of NASDAQ:PODD opened at $240.38 on Tuesday. The stock's 50-day moving average is $262.58 and its 200 day moving average is $299.57. The company has a market cap of $16.92 billion, a PE ratio of 68.68, a P/E/G ratio of 1.41 and a beta of 1.42. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to analysts' expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business's revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business posted $1.15 EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PODD. Zacks Research lowered Insulet from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 5th. Raymond James Financial decreased their price target on Insulet from $385.00 to $355.00 and set an "outperform" rating on the stock in a research note on Thursday, February 19th. The Goldman Sachs Group lowered their price objective on Insulet from $363.00 to $326.00 and set a "buy" rating for the company in a research report on Thursday, February 19th. Citigroup dropped their price objective on Insulet from $380.00 to $345.00 and set a "buy" rating for the company in a research note on Thursday, February 19th. Finally, Truist Financial cut their target price on shares of Insulet from $390.00 to $360.00 and set a "buy" rating on the stock in a report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $354.57.

Insider Activity at Insulet

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares of the company's stock, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.39% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.